Evidence map›Paper›PMID 25897422›Full record

ArticleOncoscience2015

Prognostic microRNAs in high-grade glioma reveal a link to oligodendrocyte precursor differentiation.

Josie Hayes, Helene Thygesen, Alastair Droop, Thomas A Hughes, David Westhead, Sean E Lawler, Heiko Wurdak, Susan C Short

Open access · hybridAbstract read
In one paragraph

Article in Oncoscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Josie HayesLeeds Institute of Cancer and Pathology, University of Leeds, St James's University Hospital, Leeds, UK.
Helene ThygesenLeeds Institute of Cancer and Pathology, University of Leeds, St James's University Hospital, Leeds, UK.
Alastair DroopLeeds Institute of Cancer and Pathology, University of Leeds, St James's University Hospital, Leeds, UK.
Thomas A HughesLeeds Institute of Biomedical and Clinical Sciences, University of Leeds, St James's University Hospital, Leeds, UK.
David WestheadInstitute of Molecular and Cellular Biology, Faculty of Biological Sciences and Institute of Membrane and Systems Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
Sean E LawlerDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Heiko WurdakLeeds Institute of Cancer and Pathology, University of Leeds, St James's University Hospital, Leeds, UK.
Susan C ShortLeeds Institute of Cancer and Pathology, University of Leeds, St James's University Hospital, Leeds, UK.
University of Leeds · GBSt James's University Hospital · GBHarvard University · US

Funding

Medical Research Council MR/J001171/1
6 · The paper itself

Abstract

MicroRNA expression can be exploited to define tumor prognosis and stratification for precision medicine. It remains unclear whether prognostic microRNA signatures are exclusively tumor grade and/or molecular subtype-specific, or whether common signatures of aggressive clinical behavior can be identified. Here, we defined microRNAs that are associated with good and poor prognosis in grade III and IV gliomas using data from The Cancer Genome Atlas. Pathway analysis of microRNA targets that are differentially expressed in good and poor prognosis glioma identified a link to oligodendrocyte development. Notably, a microRNA expression profile that is characteristic of a specific oligodendrocyte precursor cell type (OP1) correlates with microRNA expression from 597 of these tumors and is consistently associated with poor patient outcome in grade III and IV gliomas. Our study reveals grade-independent and subtype-independent prognostic molecular signatures in high-grade glioma and provides a framework for investigating the mechanisms of brain tumor aggressiveness.

Indexed as

astrocytomaglioblastomagliomamicroRNAoligodendrocyteprognosis

Identifiers

PMID25897422
PMCPMC4394131
OpenAlexW1962544572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.